DexCom (DXCM) is down sharply as investors react to renewed focus on the company’s Dexcom G7 mobile apps correction that the FDA has categorized as a Class I recall, the agency’s most serious recall type. The correction centers on a software design issue in the G7 and ONE+ apps that may fail to alert users about unexpected sensor failure, keeping product quality and safety concerns front-and-center for the market.

Even when a recall is addressed via a correction rather than a hardware pullback, it can still raise questions about complaint rates, support costs, and customer confidence—especially for users who depend on continuous glucose monitoring for insulin-dosing decisions. With the CGM market increasingly competitive, any perception of reliability gaps can influence switching behavior, payer conversations, and the pace of upgrades to newer platforms.

DXCM has been prone to outsized moves around guidance and confidence in the growth runway. Earlier in 2026, DexCom guided 2026 revenue to $5.16–$5.25 billion (about 11–13% growth), and management commentary acknowledged the high end of the range could sit below prevailing Street expectations at the time, which contributed to a more cautious setup for the stock. Against that backdrop, regulatory and reliability headlines can have an amplified impact on day-to-day trading.